Enduring Material

• Review the history, epidemiology, demographics, natural history, immunology, and pathophysiology that leads to increased incidence of viral hepatitis.
• Explore the medical and psychosocial drivers that make eliminating HCV difficult.
• Propose solutions to eliminate HCV in local, high-risk populations.
• Explain the growth in Hepatitis D cases and new therapies to treat the disease.
• Formulate and implement strategies for preventing, diagnosing, treating, and/or referring patients with viral hepatitis.
• Implement the newest guidance and diagnostic algorithms for portal hypertension.
• Summarize the leading causes of the progression of chronic liver disease, hepatorenal syndrome, ascites, and hepatic encephalopathy.
• Discuss the growing lists of First- and Second-Line therapies for liver cancer.
• Explore the causes and impact of alcohol on liver health and progression toward malnutrition, cirrhosis, and liver cancer
• Integrate newer treatment options for HCC approaches to reduce tumor size and number.
• Review the current therapies for PBC and clinical approaches for PSC.
• Discover the pathway and barriers to liver disease elimination and the unique challenges of special populations.
• Implement the new Fatty Liver Disease naming conventions in clinical practice.
• Dive into the reasons MASLD and MASH are fast becoming a global health emergency.
• Utilize current clinical cases to improve diagnostic and treatment skills.
• Evaluate the latest updates and scientific breakthrough from the 2023 EASL, DDW and AASLD conferences.
• Improve the health of patients infected with hepatitis virus, liver cancer, primary biliary cholangitis and other progressive liver diseases.

• The Colorado Medical Society designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this enduring material for a maximum of 10 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Sidney Barritt, MD, MSCR, FACG, FAASLD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Madrigal - Consulting - Relationship Has Not Ended
• Merck (Any division) - Advisory Committee Member - Relationship Has Not Ended
• Mirum - Advisory Committee Member - Relationship Has Not Ended
• Boehringer Ingelheim - Advisory Committee Member - Relationship Has Not Ended
• Life Edit - Consulting - Relationship Has Not Ended
• Target RWE - Consulting - Relationship Has Not Ended

Anthony Martinez, MD, AAHIVS, FAASLD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Gilead - Consulting - Relationship Has Not Ended
• Gilead - Advisory Committee Member - Relationship Has Not Ended
• Abbvie - Consulting - Relationship Has Not Ended
• Abbvie - Speaking - Relationship Has Not Ended
• Braeburn - Speaking - Relationship Has Not Ended
• cepheid - Consulting - Relationship Has Not Ended
• Madrigal - Consulting - Relationship Has Not Ended
• Arbutus - Consulting - Relationship Has Not Ended
• roche - Consulting - Relationship Has Not Ended
• Altimune - Consulting - Relationship Has Not Ended
• VBI/Syneos - Consulting - Relationship Ended

Craig McClain, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• National Institutes of Health - Contracted Research - Relationship Has Not Ended
• Veterans Administration Medical Center - Contracted Research - Relationship Has Not Ended
• Target Pharma Solutions - Contracted Research - Relationship Has Not Ended
• Altimmune - Contracted Research - Relationship Has Not Ended

Paul J. Pockros, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• ChemoMab Therapeutics - Contracted Research - Relationship Has Not Ended
• Intercept - Advisory Committee Member - Relationship Has Not Ended
• Gilead - Advisory Committee Member - Relationship Has Not Ended
• Ipsen - Advisory Committee Member - Relationship Has Not Ended
• Novo Nordisk - Ownership Interest - Relationship Has Not Ended
• UpToDate - Advisory Committee Member - Relationship Has Not Ended
• Gilead - Speakers Bureau - Relationship Has Not Ended
• Ipsen - Speakers Bureau - Relationship Has Not Ended
• Madrigal - Speakers Bureau - Relationship Has Not Ended

Amit Singal, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Genentech - Consulting - Relationship Has Not Ended
• AstraZeneca - Consulting - Relationship Has Not Ended
• Merck - Consulting - Relationship Has Not Ended
• Elevar - Advisory Committee Member - Relationship Has Not Ended
• Eisai - Consulting - Relationship Has Not Ended
• Bayer - Consulting - Relationship Has Not Ended
• Exelixis - Advisory Committee Member - Relationship Has Not Ended
• Boston Scientific - Consulting - Relationship Has Not Ended
• Sirtex - Consulting - Relationship Has Not Ended
• HistoSonics - Consulting - Relationship Has Not Ended
• FujiFilm Medical Sciences - Consulting - Relationship Has Not Ended
• HelioLiver - Consulting - Relationship Has Not Ended
• Exact Sciences - Consulting - Relationship Has Not Ended
• Abbott - Consulting - Relationship Has Not Ended
• UniversalDx - Consulting - Relationship Has Not Ended
• DELFI - Consulting - Relationship Has Not Ended
• IMCare - Consulting - Relationship Has Not Ended

Aubrey Shoe, MA, CHCP and Howard Horwitz, MPH, FACHE have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Paul J. Pockros, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• ChemoMab Therapeutics - Contracted Research - Relationship Has Not Ended
• Intercept - Advisory Committee Member - Relationship Has Not Ended
• Gilead - Advisory Committee Member - Relationship Has Not Ended
• Ipsen - Advisory Committee Member - Relationship Has Not Ended
• Novo Nordisk - Ownership Interest - Relationship Has Not Ended
• UpToDate - Advisory Committee Member - Relationship Has Not Ended
• Gilead - Speakers Bureau - Relationship Has Not Ended
• Ipsen - Speakers Bureau - Relationship Has Not Ended
• Madrigal - Speakers Bureau - Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

100 %

1/15/2025